HK1206279A1 - Pharmaceutical compositions comprising glycerol esters - Google Patents

Pharmaceutical compositions comprising glycerol esters

Info

Publication number
HK1206279A1
HK1206279A1 HK15107054.1A HK15107054A HK1206279A1 HK 1206279 A1 HK1206279 A1 HK 1206279A1 HK 15107054 A HK15107054 A HK 15107054A HK 1206279 A1 HK1206279 A1 HK 1206279A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical compositions
glycerol esters
glycerol
esters
pharmaceutical
Prior art date
Application number
HK15107054.1A
Other languages
English (en)
Chinese (zh)
Inventor
Jason M Perry
Magali B Hickey
Julius F Remenar
Jennifer Vandiver
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of HK1206279A1 publication Critical patent/HK1206279A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK15107054.1A 2012-03-19 2015-07-23 Pharmaceutical compositions comprising glycerol esters HK1206279A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261612731P 2012-03-19 2012-03-19
PCT/US2013/030933 WO2013142202A1 (en) 2012-03-19 2013-03-13 Pharmaceutical compositions comprising glycerol esters

Publications (1)

Publication Number Publication Date
HK1206279A1 true HK1206279A1 (en) 2016-01-08

Family

ID=49223212

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107054.1A HK1206279A1 (en) 2012-03-19 2015-07-23 Pharmaceutical compositions comprising glycerol esters

Country Status (9)

Country Link
US (1) US9993556B2 (xx)
EP (1) EP2827867B1 (xx)
JP (1) JP6219918B2 (xx)
AU (1) AU2013235523B9 (xx)
CA (1) CA2867123C (xx)
ES (1) ES2764383T3 (xx)
HK (1) HK1206279A1 (xx)
NZ (1) NZ630703A (xx)
WO (1) WO2013142202A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56352B2 (sr) * 2009-06-25 2023-02-28 Alkermes Pharma Ireland Ltd Heterociklična jedinjenja za lečenje neuroloških i psiholoških poremećaja
LT3156056T (lt) 2011-03-18 2024-02-26 Alkermes Pharma Ireland Limited Farmacinės kompozicijos, apimančios sorbitano esterius
JP6333802B2 (ja) 2012-03-19 2018-05-30 アルカームス ファーマ アイルランド リミテッド ベンジルアルコールを含む医薬組成物
EP2827867B1 (en) 2012-03-19 2019-11-06 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
AU2013235519C1 (en) 2012-03-19 2018-04-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
EP2897592B1 (en) 2012-09-19 2020-02-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
CN106132415A (zh) 2014-03-20 2016-11-16 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
US20170196802A1 (en) * 2016-01-08 2017-07-13 Abon Pharmaceuticals, Llc Long Acting Injectable Formulations
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN110669057A (zh) * 2018-07-02 2020-01-10 成都阿奇生物医药科技有限公司 一种奥氮平衍生物及其制备方法和用途

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2418499A (en) 1944-06-20 1947-04-08 Du Pont 2-alkoxymethylmercapto-thiazoles and thiazolines and a process for preparing the same
DE1273533B (de) 1962-09-08 1968-07-25 Hoechst Ag Verfahren zur Herstellung von N-(ª‡-Alkoxy-alkyl)-carbonsaeureamiden
NL128370C (xx) 1964-08-28
US3523121A (en) 1967-03-09 1970-08-04 Rohm & Haas Certain 2-carbamoyl-3-isothiazolenes
US3573308A (en) 1969-04-03 1971-03-30 Hoffmann La Roche 3-lower alkoxy methyl-3,4-dihydro-4-hydroxy-4-aryl quinazolin-2(1h) ones and related compounds
US3957808A (en) 1969-09-03 1976-05-18 Rohm And Haas Company 3-alkoxyisothiazoles
US4727151A (en) 1974-06-24 1988-02-23 Interx Research Corporation Labile quaternary ammonium salts as prodrugs
US3998815A (en) 1974-06-24 1976-12-21 Interx Research Corporation 1-hydrocarbonoyloxymethyl-3-carbamoyl or 3-carboethoxy-pyridinium salts
US4204065A (en) 1975-09-22 1980-05-20 Interx Research Corporation Soft quaternary surface active agents and method of using same
US4260769A (en) 1977-04-22 1981-04-07 Interx Research Corporation 5,5-Diphenylhydantoins
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS568318A (en) 1979-06-28 1981-01-28 Janssen Pharmaceutica Nv Non oral long acting composition of haloperidol and bromperidol derivative
DE3149010A1 (de) 1981-12-10 1983-07-07 A. Nattermann & Cie GmbH, 5000 Köln (+)-2-(1-(2,6-dichlorphenoxy)-ethyl)-1,3- diazacyclopent-2-en, dessen herstellung und seine verwendung in pharamazeutischen praeparaten
US4428935A (en) 1982-05-24 1984-01-31 Pfizer Inc. Penicillanic acid dioxide prodrug
IT1212743B (it) 1983-05-17 1989-11-30 Dompe Farmaceutici Spa Sali quaternari di derivati di benzo[ 1,4 ]diazepinonici,pirido [1,4]benzodiazepinonici,prido [1,5]benzodiazepinonici e loro atti vita' farmacologica
JPS602331A (ja) * 1983-06-20 1985-01-08 Yoshino Kogyosho Co Ltd 飽和ポリエステル樹脂製壜の成形方法
US4760057A (en) 1983-06-23 1988-07-26 Merck & Co., Inc. (Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs
DK302883D0 (da) 1983-06-30 1983-06-30 Hans Bundgaard Allopurinol prodrugs
DE3544134A1 (de) 1984-12-15 1986-06-19 Mitsubishi Chemical Industries Ltd., Tokio/Tokyo Verfahren zur herstellung von n-((alpha)-alkoxyethyl) pyrrolidon
GB8513754D0 (en) 1985-05-31 1985-07-03 Jones T R Anti-cancer quinazoline derivatives
DK588486A (da) 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US4925860A (en) 1987-08-05 1990-05-15 E. I. Du Pont De Nemours And Company Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5350747A (en) 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
WO1991000863A1 (en) 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
JP2800953B2 (ja) * 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5206386A (en) 1991-03-20 1993-04-27 Isp Investments Inc. Controlled release N-substituted pyrrolidone esters and process for the use thereof
MX9201991A (es) 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
TW226016B (xx) 1991-12-30 1994-07-01 Sterling Winthrop Inc
US5462934A (en) 1992-03-09 1995-10-31 Takeda Chemical Industries Condensed heterocyclic ketone derivatives and their use
WO1993025197A1 (en) 1992-06-12 1993-12-23 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
WO1994020508A1 (en) 1993-03-08 1994-09-15 Eisai Co., Ltd. Phosphonic acid derivatives
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
DE4439493A1 (de) 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
JP3571795B2 (ja) 1995-04-18 2004-09-29 株式会社日本触媒 N−(1−アルキルオキシアルキル)カルバメート類の気相分子内脱アルコール反応用触媒およびn−ビニルカルバメート類の製造方法
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
IL126203A (en) 1996-03-25 2002-12-01 Lilly Co Eli A synergistic painkiller that contains olenzapine and another painkiller
DE19619819A1 (de) 1996-05-16 1997-11-20 Boehringer Mannheim Gmbh Neue Thiazolidindione, Verfahren zu ihrer Herstellung und diese enthaltenden Arzneimittel
EP0925061B1 (en) 1996-08-22 2005-12-28 Jagotec Ag Compositions comprising microparticles of water-insoluble substances and method for preparing same
ES2210769T3 (es) 1997-06-13 2004-07-01 Cydex Inc. Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua.
AU752552C (en) 1997-09-30 2003-09-11 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
CA2317008C (en) 1997-12-31 2009-01-20 The University Of Kansas Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
EP1114028B1 (en) 1998-08-26 2006-11-29 Aventis Pharma Limited Aza-bicycles which modulate the inhibition of cell adhesion
FR2783519B1 (fr) 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20060034937A1 (en) 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
MY128449A (en) 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6656505B2 (en) 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
US20030049320A1 (en) 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
EP1368327B1 (en) 2001-02-14 2004-10-20 Warner-Lambert Company LLC Benzo thiadiazine matrix metalloproteinase inhibitors
US20060293217A1 (en) 2001-03-19 2006-12-28 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
AU2002258563A1 (en) 2001-03-19 2002-10-03 Praecis Pharmaceuticals Incorporated Pharmaceutical formulations for sustained release
EP1414798A2 (en) 2001-04-03 2004-05-06 Aryx Therapeutics Ultrashort-acting opioids for transdermal application
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
DE60325025D1 (de) 2002-02-15 2009-01-15 Glaxo Group Ltd Modulatoren des vanilloidrezeptors
JP4667867B2 (ja) 2002-08-02 2011-04-13 メルク・シャープ・エンド・ドーム・コーポレイション 置換フロ[2,3−b]ピリジン誘導体
ES2322953T3 (es) 2002-08-20 2009-07-02 Bristol-Myers Squibb Company Formulacion del complejo de aripiprazol y procedimiento.
WO2004026864A1 (en) 2002-09-17 2004-04-01 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
US7148211B2 (en) 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20050020690A1 (en) 2002-12-18 2005-01-27 Algorx Infiltration of capsaicin into surgical sites and open wounds
EP1587506B1 (en) 2002-12-18 2008-07-23 Algorx Administration of capsaicinoids
DE10303669A1 (de) 2003-01-28 2004-07-29 Hans-Knöll-Institut für Naturstoff-Forschung e.V. Tetraalkylammoniumsalze vom Kohlensäureestertyp, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
AU2004228668B2 (en) 2003-04-03 2011-10-27 Park Funding, Llc PI-3 kinase inhibitor prodrugs
AU2004243096B2 (en) 2003-05-23 2008-12-18 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and mood stabilizers for treating mood disorders
US7371395B2 (en) 2003-07-24 2008-05-13 Merial Limited Vaccine formulations
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
JP4231051B2 (ja) * 2003-08-29 2009-02-25 株式会社東芝 測定対象物質の濃度測定方法、測定対象物質の濃度測定用キット及びセンサチップ
UA82561C2 (uk) 2003-10-23 2008-04-25 Оцука Фармасьютикалз Ко., Лтд. Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії
BRPI0418255A (pt) 2003-12-31 2007-04-17 Warner Lambert Co derivados de piperazina e piperidina n-substituìdos
CN1917882A (zh) 2004-02-13 2007-02-21 辉瑞产品公司 非典型抗精神病药物与促肾上腺皮质激素释放因子拮抗剂的治疗剂组合
US7169803B2 (en) 2004-03-15 2007-01-30 Bristol-Myers Squibb Company N-substituted prodrugs of fluorooxindoles
US7119214B2 (en) 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
GB2413795A (en) 2004-05-05 2005-11-09 Cipla Ltd Process for the preparation of rosiglitazone
WO2006037090A2 (en) 2004-09-28 2006-04-06 Purdue Research Foundation Drug-phosphate conjugates as prodrugs
AU2005307797B2 (en) * 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
WO2006082588A2 (en) 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
WO2006090273A2 (en) 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
WO2006134864A1 (ja) 2005-06-13 2006-12-21 Dainippon Sumitomo Pharma Co., Ltd. 可溶化型製剤
EP2279727A3 (en) 2005-09-15 2011-10-05 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
EP1777222A1 (en) 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US20070185069A1 (en) 2005-11-14 2007-08-09 Plum Stacy M Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
US20090068290A1 (en) 2006-08-31 2009-03-12 Michel Bourin Bifeprunox doses for treating schizophrenia
CL2007002684A1 (es) 2006-09-15 2008-06-27 Astrazeneca Ab Targacept Inc Combinacion que comprende un antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina; composicion farmaceutica que la comprende; kit farmaceutico; y uso para tratar perjuicio cognitivo y/o trastorno psicoticos.
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
KR20090086627A (ko) 2006-12-05 2009-08-13 노이로제스엑스, 인코포레이티드 프로드러그 및 그것의 제조 및 사용 방법
AU2007334343A1 (en) 2006-12-15 2008-06-26 Ordway Research Institute, Inc. Treatments of therapy-resistant diseases comprising drug combinations
EP1961412A1 (en) * 2006-12-27 2008-08-27 LEK Pharmaceuticals D.D. Self-microemulsifying drug delivery systems
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
CA2681506C (en) 2007-03-19 2016-05-24 Perry Peters Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
NZ580167A (en) 2007-04-04 2012-02-24 Merck Sharp & Dohme Hexahydro-1h-4,7-methanoisoindole-1,3-dione compounds and their use as atypical antipsychotic agents
WO2009012096A2 (en) 2007-07-18 2009-01-22 Research Development Foundation Improved therapeutic methods and compositions comprising chroman ring compounds
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009052467A1 (en) 2007-10-19 2009-04-23 Board Of Regents Of The University Of Texas System Methods of identifying pi-3-kinase inhibitor resistance
CL2008003305A1 (es) 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
CN101932327A (zh) 2007-12-19 2010-12-29 詹森药业有限公司 与长效注射用帕潘立酮酯相关的给药方案
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
US9161943B2 (en) 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
WO2009126931A2 (en) 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
KR20110050549A (ko) 2008-09-03 2011-05-13 버텍스 파마슈티칼스 인코포레이티드 공-결정 및 이를 포함하는 제약 제제
CA2750400A1 (en) 2009-01-26 2010-07-29 Egalet A/S Controlled release formulations with continuous efficacy
US20100286136A1 (en) 2009-05-08 2010-11-11 Simon Jones Dihydronaphthyridinyl and related compounds for use in treating ophthalmological disorders
US8686009B2 (en) 2009-06-25 2014-04-01 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
RS56352B2 (sr) * 2009-06-25 2023-02-28 Alkermes Pharma Ireland Ltd Heterociklična jedinjenja za lečenje neuroloških i psiholoških poremećaja
AU2010313290A1 (en) 2009-10-30 2012-05-17 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
EP2521711B1 (en) 2010-01-07 2017-08-16 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
WO2011084849A1 (en) 2010-01-07 2011-07-14 Alkermes, Inc. Diaryldiazepine prodrugs for the treatment of neurological and psychological disorders
US20110166156A1 (en) 2010-01-07 2011-07-07 Alkermes, Inc. Prodrugs for the Treatment of Schizophrenia and Bipolar Disease
WO2011084851A1 (en) 2010-01-07 2011-07-14 Alkermes, Inc. Asenapine produrugs
AU2010339691B2 (en) 2010-01-07 2015-04-02 Alkermes Pharma Ireland Limited Prodrugs of heteraromatic compounds
CN104111233B (zh) 2010-02-16 2017-09-15 浜松光子学株式会社 气体浓度计算装置及气体浓度测量模块
EP2566329B1 (en) 2010-05-04 2020-09-09 Alkermes Pharma Ireland Limited Process for synthesizing oxidized lactam compounds
ES2691671T3 (es) 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
LT3156056T (lt) 2011-03-18 2024-02-26 Alkermes Pharma Ireland Limited Farmacinės kompozicijos, apimančios sorbitano esterius
AU2013235519C1 (en) 2012-03-19 2018-04-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
EP2827867B1 (en) 2012-03-19 2019-11-06 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
JP6333802B2 (ja) 2012-03-19 2018-05-30 アルカームス ファーマ アイルランド リミテッド ベンジルアルコールを含む医薬組成物
EP2897592B1 (en) 2012-09-19 2020-02-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
CN106132415A (zh) 2014-03-20 2016-11-16 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂

Also Published As

Publication number Publication date
AU2013235523B2 (en) 2017-12-07
EP2827867A1 (en) 2015-01-28
ES2764383T3 (es) 2020-06-03
NZ630703A (en) 2017-02-24
US9993556B2 (en) 2018-06-12
EP2827867B1 (en) 2019-11-06
AU2013235523B9 (en) 2018-01-04
CA2867123C (en) 2021-02-16
AU2013235523A1 (en) 2014-09-25
CA2867123A1 (en) 2013-09-26
EP2827867A4 (en) 2015-11-11
JP2015510930A (ja) 2015-04-13
JP6219918B2 (ja) 2017-10-25
US20130267504A1 (en) 2013-10-10
WO2013142202A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
IL286348A (en) Pharmaceutical preparations that include allopregnanolone
IL276012A (en) Pharmaceutical preparations containing sorbitan esters
IL252566B (en) Pharmacy preparations and methods
HK1209638A1 (en) Pharmaceutical compositions
HK1209147A1 (en) Cellulose ester composition
HK1206279A1 (en) Pharmaceutical compositions comprising glycerol esters
ZA201501930B (en) Pharmaceutical composition
HK1206595A1 (en) Pharmaceutical compositions comprising benzyl alcohol
HK1206596A1 (en) Pharmaceutical compositions comprising fatty acid esters
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
HK1208178A1 (en) Racecadotril lipid compositions
ZA201501553B (en) Pharmaceutical compositions comprising flurbiprofen
ZA201502987B (en) Pharmaceutical composition
EP2897590A4 (en) PHARMACEUTICAL COMPOSITION
GB201211153D0 (en) Pharmaceutical compositions
GB201208315D0 (en) Pharmaceutical methods and compositions
EP2851078A4 (en) PHARMACEUTICAL COMPOSITION
IL238075A0 (en) pharmaceutical preparations
GB201219234D0 (en) Pharmaceutical compositions
GB201213303D0 (en) Pharmaceutical compositions
GB201204810D0 (en) Pharmaceutical compositions
ZA201400751B (en) Pharmaceutical composition